Nebulized Ensifentrine Shows Promise as Add-on Therapy

Nebulized Ensifentrine Shows Promise as Add-on Therapy

293209

Nebulized Ensifentrine Shows Promise as Add-on Therapy

Verona Pharma has announced positive efficacy and safety results about using nebulized ensifentrine as an add-on therapy to tiotropium (Spiriva Respimat) for treating symptomatic chronic obstructive pulmonary disease (COPD). Results from the Phase 2b clinical trial (NCT03937479) show that ensifentrine treatment, combined with maintenance tiotropium, results in significant improvements in lung function and quality of life in COPD patients who have impaired lung function and disease symptoms. “These data in symptomatic COPD patients on maintenance bronchodilator therapy…

You must be logged in to read/download the full post.